Results 131 to 140 of about 21,874 (160)

Lapatinib as a Chemotherapeutic Drug

Recent Patents on Anti-Cancer Drug Discovery, 2009
Human epidermal growth factor receptor (HER) signaling is frequently associated with the development and progression of several types of cancers. Both the MAPK and the PI3K/Akt pathways have been implicated as effectors of HER signaling by promoting anti-apoptotic and pro-proliferative effects in cancer cells. As a result, many anti-HER drugs have been
openaire   +2 more sources

Lapatinib

Reactions Weekly, 2013
  +4 more sources

Lapatinib

Drugs of the Future, 2005
null Boyd, B., null Bozzo, J., null Castaner, J., null Bayes, M.   +3 more
openaire   +1 more source

Lapatinib

Reactions Weekly, 2008
  +4 more sources

Lapatinib

Reactions Weekly, 2011
openaire   +2 more sources

Lapatinib

Reactions Weekly, 2015
  +4 more sources

Lapatinib

Reactions Weekly, 2021
openaire   +1 more source

The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats

Cancer Chemotherapy and Pharmacology, 2020
Dorothy Keefe, Daniel Thorpe, Bronwen Mayo   +2 more
exaly  

Lapatinib

Reactions Weekly, 2017
openaire   +2 more sources

Phase II study on lapatinib in advanced EGFR-positive chordoma

Annals of Oncology, 2013
Luigi Mariani, Silvia Stacchiotti, Elena Tamborini   +2 more
exaly